Akers Biosciences Inc. (AKER)

[knuts4oe]

Dr Adam Kaplan, who earlier in December officially became the Chief Scientific Officer at MyMD Pharmaceuticals, did an excellent job of detailing the significant advantages of dosing with MYMD-1, in the "Akers Biosciences Business Update".
He points out that it is an excellent selective TNFa blocker which makes it a formidable competetor in the $40 billion market for Humira and other TNFa blockers.
It is also an excellent anti-inflammitory which should be useful in treating any disease or medical condition whose name ends in "itis".
It is also a potent anti-depressant which would have application in countless medical conditions.
All of this comes to the Akers/MyMD merger from MyMD. Akers brings only its questionable relationship with Premas for a vaccine, and its ability to raise funds for MyMD. Thus its 20% share in the final MyMD Pharmaceuticals.